Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers | Zendy

Shelly McNeil | Zendy; Scott A. Halperin | Zendy; Joanne M. Langley | Zendy; B R Smith | Zendy; Andrew E. Warren | Zendy; Geoffrey P. Sharratt | Zendy; Darlene Baxendale | Zendy; Mark A. Reddish | Zendy; Minhua Hu | Zendy; Steven D. Stroop | Zendy; Joel Linden | Zendy; Louis Fries | Zendy; Peter Vink | Zendy; James B. Dale | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of 26-Valent Group A Streptococcus Vaccine in Healthy Adult Volunteers

Author(s) -

Shelly McNeil,

Scott A. Halperin,

Joanne M. Langley,

B R Smith,

Andrew E. Warren,

Geoffrey P. Sharratt,

Darlene Baxendale,

Mark A. Reddish,

Minhua Hu,

Steven D. Stroop,

Joel Linden,

Louis Fries,

Peter Vink,

James B. Dale

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/444458

Subject(s) - immunogenicity , medicine , reactogenicity , antibody , antigen , streptococcus pyogenes , streptococcus , immunology , antibody titer , pharyngitis , antibody opsonization , microbiology and biotechnology , titer , virology , biology , staphylococcus aureus , bacteria , genetics , opsonin

Group A streptococcus (GAS) causes illness ranging from uncomplicated pharyngitis to life-threatening necrotizing fasciitis, toxic shock, and rheumatic fever. Attempts to develop an M protein-based vaccine have been hindered by the fact that some M proteins elicit both protective antibodies and antibodies that cross-react with human tissues. New molecular techniques have allowed the previous obstacles to be largely overcome.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research